These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 31041232)

  • 21. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
    Gupta A
    Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
    Muthukrishnan J; Dawra S; Marwaha V; Bishnoi JS; Narayanan CS
    Indian J Endocrinol Metab; 2012 Dec; 16(Suppl 2):S474-6. PubMed ID: 23565471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence.
    Sahay RK; Mittal V; Gopal GR; Kota S; Goyal G; Abhyankar M; Revenkar S
    Cureus; 2020 Sep; 12(9):e10700. PubMed ID: 33133865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years' duration--a randomised, double-blind, placebo-controlled, cross-over study.
    Nybäck-Nakell Å; Adamson U; Lins PE; Landstedt-Hallin L
    Diabetes Res Clin Pract; 2014 Feb; 103(2):286-91. PubMed ID: 24485398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Handelsman Y; Lauring B; Gantz I; Iredale C; O'Neill EA; Wei Z; Suryawanshi S; Kaufman KD; Engel SS; Lai E
    Curr Med Res Opin; 2017 Oct; 33(10):1861-1868. PubMed ID: 28548024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S; Saxena GN; Keshwani P; Gupta R
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study.
    Yoon KH; Shin JA; Kwon HS; Lee SH; Min KW; Ahn YB; Yoo SJ; Ahn KJ; Park SW; Lee KW; Sung YA; Park TS; Kim MS; Kim YK; Nam MS; Kim HS; Park IeB; Park JS; Woo JT; Son HY
    Diabetes Metab J; 2011 Feb; 35(1):26-33. PubMed ID: 21537410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vildagliptin: a review of its use in type 2 diabetes mellitus.
    Keating GM
    Drugs; 2010 Nov; 70(16):2089-112. PubMed ID: 20964454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. QTc prolongation Safety and Effectiveness of Teneligliptin in Indian patients with type 2 Diabetes Mellitus: A real world study (QSET 2).
    Saboo B; Ghosh S; Tiwaskar M; Chawla R
    Diabetes Metab Syndr; 2021; 15(5):102264. PubMed ID: 34488059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors Influencing the Prescribing Preferences of Physicians for Drug-Naive Patients with Type 2 Diabetes Mellitus in the Real-World Setting in Japan: Insight from a Web Survey.
    Murayama H; Imai K; Odawara M
    Diabetes Ther; 2018 Jun; 9(3):1185-1199. PubMed ID: 29696567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative evaluation of efficacy and safety of combination of metformin-vidagliptin versus metfromin-glimepiride in most frequently used doses in patients of type 2 diabetes mellitus with inadequately controlled metformin monotherapy-A randomised open label study.
    Gupta S; Khajuria V; Tandon VR; Mahajan A; Gillani ZH
    Perspect Clin Res; 2015; 6(3):163-8. PubMed ID: 26229753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
    Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-World Observational Study of Glimepiride and Metformin Fixed-Dose Combination Along With Insulin in the Management of Type 2 Diabetes Mellitus: Indian Experience.
    Prasanna Kumar KM; Seshadri K; Aravind SR; Deb P; Modi KD; Gopal RA; G VK; Moses CA; Abhyankar M; Revenkar S
    Cureus; 2021 Jan; 13(1):e13020. PubMed ID: 33665047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes.
    Takahara M; Shiraiwa T; Matsuoka TA; Yamamoto K; Maeno Y; Shiraiwa Y; Yoshida Y; Katakami N; Iijima H; Katsumata H; Arakawa K; Hashimoto T; Shimomura I
    Diabetes Metab Syndr Obes; 2020; 13():4457-4468. PubMed ID: 33244248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Review on Affordable Combinations in Type 2 Diabetes Care: Exploring the Cost-Effective Potential of Glipizide + Metformin and Glimepiride + Metformin + Pioglitazone.
    Shaikh S; Vaidya V; Gupta A; Kulkarni R; Joshi A; Kulkarni M; Sharma V; Revankar S
    Cureus; 2024 May; 16(5):e59850. PubMed ID: 38854289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.